0001795091 2025-12-31 2025-01-01 2025-12-31 0001795091 2025-01-01 2025-12-31 DEF 14A 0001795091 false OS THERAPIES INCORPORATED Our board of directors has not adopted a formal insider trading policy governing the purchase, sale and/or other disposition of our securities by the Company, our directors, officers, employees and consultants that is reasonably designed to promote compliance with insider trading laws, rules and regulations, and any applicable NYSE American listing standards. false <p style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">During 2025, we did not grant any new awards of stock options, stock appreciation rights or similar option<span>-like</span> instruments within the period beginning four business days before or ending one business day after the filing of a Quarterly Report on Form 10<span>-Q</span>, an Annual Report on Form 10<span>-K</span> or Current Report on Form 8<span>-K</span> that disclosed material nonpublic information.</p><p style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;"> We do not currently maintain a formal policy or practice governing the timing of such awards in relation to our disclosure of material nonpublic information. However, should we elect to grant new awards of stock options, stock appreciation rights or similar option-like instruments in the future, the Board will assess and implement appropriate measures to ensure alignment with best practices and regulatory guidance. </p> false We do not currently maintain a formal policy or practice governing the timing of such awards in relation to our disclosure of material nonpublic information. <p style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:justify;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with Rule 10D<span>-1</span> under the Exchange Act and the listing standards of the NYSE American, we have adopted an incentive compensation clawback policy that requires the recovery of erroneously awarded incentive<span>-based</span> compensation from current and former executive officers in the event of an accounting restatement. The policy applies to incentive<span>-based</span> compensation received by covered officers during the three completed fiscal years immediately preceding the date on which we are required to prepare a restatement and covers compensation that is in excess of what would have been paid under the restated financial statements. A copy of the clawback policy is filed as an exhibit to our Annual Report on Form 10<span>-K</span> for the fiscal year ended December 31, 2025.</p> 2025-12-31